TG Therapeutics | 10-Q: Quarterly report
TG Therapeutics | 8-K: TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
TG Therapeutics | ARS: Annual Report to Security Holders
TG Therapeutics | DEFA14A: Others
TG Therapeutics | DEF 14A: Definitive information statements
TG Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
TG Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Lonial Sagar
TG Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Charney Laurence N
TG Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
TG Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
TG Therapeutics | 10-K: Annual report
TG Therapeutics | 8-K: TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
TG Therapeutics | 5: Annual statement of changes in beneficial ownership of securities-Officer Power Sean A
TG Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Darwin Global Management, Ltd.(2.7%),Dr. Abhishek Trehan(2.7%), etc.
TG Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(9.03%)
TG Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(7.1%)
TG Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-STATE STREET CORPORATION(5.45%)
TG Therapeutics | 8-K: Current report
TG Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Charney Laurence N
TG Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer WEISS MICHAEL S
No Data